10-12 October 2017
Boston, USA

Day One
Wednesday October 11, 2017

Day Two
Thursday October 12, 2017

07.45
Registration & Coffee

08.45
Chairman’s Opening Remarks

  • Monica Luchi former CMO & Executive VP , Immune Pharmaceuticals

09.00
Opening Keynote Panel Discussion: A Therapeutic Revolution in Dermatology – Bridging the Gaps & Opportunities

Synopsis

• Addressing the evolving landscape, growing interest and developments in the
dermatology drug development space
• Analyzing the paradigm shift from topical to systemic treatment approaches – tacklingsymptoms vs. causes
• Unmet needs – evaluating the ROI of drug development for rare dermatological conditions
• Outlining where we are and where we are going – important learnings to date and perspectives on future directions

Optimizing Discovery & Preclinical Development in Dermatology

09.45
Precision Medicine in Dermatology – Revolutionizing R&D & Providing Optimal Treatment for Patients

Synopsis

• Assessing how biomarkers provide a unique opportunity to improve disease
understanding: Identifying distinct subtypes (different presentations and different response to treatment), unique disease signatures and early changes in biomarker profiles
• Exploring how early response prediction can reduce late stage attrition
• 2020 – the era of biologics
• Applying in-depth disease and pathway understanding to identify new biologics targets
• Addressing single gen orphan diseases with biologics
• Applying biomarkers to support precision medicine
• Creating the win-win for the Four Ps (Patient, Physician, Payer, Pharma) with Precision Medicine

10.15
Morning Refreshments & Speed Networking

11.45
Translational Research in Dermatology – Setting the Course for Successful/Accelerated Clinical Development

  • Ernst Kriehuber Director Translational Medicine, Dermatology & Immune Mediated Diseases, Novartis Institutes for Biomedical Research

Synopsis

• Exploring how to match the right mechanism with the right indication
• Accelerating clinical development by implementing PD in FIH studies
• Exploring PK-PD for indication expansion

12.15
Skin Biology – A Valuable Tool for the Innovation & Development of Novel Therapeutic Alternatives in Dermatology

Synopsis

  • Introducing EnDev Laboratories and the Skin Biology capabilities
  •  Reviewing different in vivo/ex vivo/in vitro skin models available
  • Describing the pre-clinical strategy to de-risk dermal drug development
  • Presenting case studies supporting the use of skin biology for innovation and drug development

12.45
Lunch & Networking

Advancing Topical & Small Molecule Drug Development

13.45
Addressing the Innovation Gap in Topical Dermatology Drug Development

Synopsis

• Analyzing the revolution in how moderate to severe dermatologic diseases (e.g., psoriasis
and AD) are now treated in a targeted way with the biologics
• Looking at the innovation gap in topical drug development with many patients still primarily using topical steroids
• Describing the need for a novel targeted topical approach to fill the innovation gap in treatment for the mild to moderate (80-90%) patient population with dermatologic diseases
• Modifying potent small molecules that address key immune targets of psoriasis and atopic dermatitis with a “Topical by Design” approach
• Exploring how “Topical by Design” also results in a favorable safety profile with Low Systemic Exposure (LSE)

14.15
Key considerations in designing topical formulations

  • Sujatha Sonti VP, Topical Product Development , GlaxoSmithKline

Synopsis

• Exploring Target Product Profiles in dermatology applications
• Discussing the latest advances in formulation, analytical and process development technologies
• Analyzing formulation selection criteria

14.45
Targeting Diseases Using Topical Treatments with Spherical Nucleic Acids

Synopsis

• Treating dermatological diseases locally using topically applied drugs – analyzing the Exicure approach
• Exploring Spherical Nucleic Acids – an innovative approach to treating patients using underlying biology by targeting a disease at its genetic source
• Analyzing early clinical data and the shown success using this approach via a TNF pathway in patients with psoriasis
• Tackling other diseases with known genetic drivers

15.15
Innovations to Mitigate Risk in Topical Formulation Development

Synopsis

  • Trends in topical and transdermal drug development
  • Innovations impacting the trends
  • Benefits innovations have brought to topical dermatological medicines development

15.25
Afternoon Refreshments & Networking

15.55
Innovation in Oral Immunomodulators for the Treatment of Psoriasis & Other Dermatological Conditions

Synopsis

• Overviewing Prurisol: A new small molecule under investigation for the treatment of psoriasis
• Exploring HDP Mimetics: Understanding the mechanism of action of endogenous host defence peptides (HDPs) as enhancers of immunomodulatory functions
• Analyzing Brilacidin as a novel small molecule for the treatment of bacterial infections, with successful Phase II b clinical trial results for acute bacterial skin and skin structure infection (ABSSSI)

16.25
Panel Discussion: Debating the Therapeutic Developments in Topicals

Synopsis

• Taking risks in early stages to develop new and innovative topicals
• Addressing the big pharma vs. smaller biotech paradigms and perspectives
• Analyzing the next steps in developing increasingly efficient dermatological topical treatments

17.10
Chairman’s Closing Remarks

  • Monica Luchi former CMO & Executive VP , Immune Pharmaceuticals